Search - tctmd.com

Displaying 1 - 20 of 26

Sort: Relevancy | Date

Presentation ACC 2024

Principal Results From the Double-blind, Placebo-controlled ULTIMATE-DAPT Trial

Presenter: Gregg W Stone

April 07, 2024

Presentation AHA 2022

Bivalirudin Plus a High-dose Infusion Versus Heparin Monotherapy in Patients with STEMI Undergoing Primary PCI: The BRIGHT-4 Trial

Presenter: Gregg W. Stone

November 07, 2022

Presentation Fellows 2018

ACS Pharmacology for the Interventionalist

Presenter: Duane S. Pinto, Gregg W. Stone

April 13, 2018

Presentation LAA 2017

Warfarin and NOACs in Non-Valvular Atrial Fibrillation

Presenter: Gregg W. Stone

July 21, 2017

Presentation

Timing of Clopidogrel Loading in US Practice

Presenter: Gregg W. Stone

February 08, 2016

Presentation

Post-ESC_15 Late-Breaking Trial Webcast: MATRIX Duration, OPTIDUAL, and PLATFORM

Presenter: Gregg W. Stone

September 15, 2015

Presentation Fellows 2015

Antiplatelet Therapy for the Interventionalist

Presenter: Manish A. Parikh, Roxana Mehran, Gregg W. Stone

May 15, 2015

Presentation

ACC 2015 Late Breaking Trials: PCI Access and Anticoagulation Trials

Presenter: Gregg W. Stone

April 14, 2015

Presentation

Bivalirudin vs Heparin With or Without GPIs in Patients With STEMI Undergoing Primary PCI

Presenter: Gregg W. Stone

January 05, 2015

Presentation

AHA 2014 Late Breaking Trials: Duration of Dual Anti-platelet Therapy after Stenting

Presenter: Gregg W. Stone

December 01, 2014

Presentation TCT 2014

Con: Follow the Data and Save the Patient!

Presenter: Adrian P. Banning, Gregg W. Stone

September 16, 2014

Presentation TCT 2014

The Data Strongly Support Bivalirudin!

Presenter: Gregg W. Stone

September 14, 2014

Presentation

Pharmacotherapy for Primary PCI - Late Breaking Trials: EUROMAX, HEAT-PPCI, BRIGHT, and BRAVE 4

Presenter: Gregg W. Stone

July 23, 2014

Presentation TCT 2013

EUROMAX: Critical Appraisal and Clinical Implications

Presenter: Gregg Stone

October 30, 2013

Presentation

Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of DES

Presenter: Gregg W. Stone

July 30, 2013

Presentation

Post ACC Wrap-up CHAMPION PHOENIX and STREAM

Presenter: Gregg W. Stone

March 29, 2013

Presentation

ADAPT-DES One-Year Results: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel and Aspirin Hyporesponsiveness on Patient Outcomes

Presenter: Gregg W. Stone

March 26, 2013

Presentation TCT 2013

Discontinuation of Long-Term Clopidogrel Therapy is Associated with Death and Myocardial Infarction after Saphenous Vein Graft Percutaneous Coronary Intervention

Presenter: Amit Sachdeva, Sumati Bavisetty, Gerald Beckham, Albert Shen, Vicken Aharonian, Prakash Mansukhani, Gregg Stone, Martin Leon, Jeffrey Moses, Naing Moore, Ric Hyett, Richard Contreras, Somjot Brar

January 31, 2013

Presentation TCT 2013

Can the Rate of Acute Stent Thrombosis with Bivalirudin Anticoagulation During Primary PCI in STEMI be Reduced with Modified Pharmacologic Regimens?

Presenter: Andreas Baumbach, Harold Dauerman, Bernardo Cortese, Martial Hamon, Jayne Prats, Efthymios Deliargyris, Roxana Mehran, Gregg Stone

January 31, 2013

Presentation TCT 2012

ADAPT-DES One Year: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel and Aspirin Hyporesponsiveness on Patient Outcomes

Presenter: Gregg Stone

October 25, 2012

Advertisement

Principal Results From the Double-blind, Placebo-controlled ULTIMATE-DAPT Trial

Bivalirudin Plus a High-dose Infusion Versus Heparin Monotherapy in Patients with STEMI Undergoing Primary PCI: The BRIGHT-4 Trial

ACS Pharmacology for the Interventionalist

Warfarin and NOACs in Non-Valvular Atrial Fibrillation

Timing of Clopidogrel Loading in US Practice

Post-ESC_15 Late-Breaking Trial Webcast: MATRIX Duration, OPTIDUAL, and PLATFORM

Antiplatelet Therapy for the Interventionalist

ACC 2015 Late Breaking Trials: PCI Access and Anticoagulation Trials

Bivalirudin vs Heparin With or Without GPIs in Patients With STEMI Undergoing Primary PCI

AHA 2014 Late Breaking Trials: Duration of Dual Anti-platelet Therapy after Stenting

Con: Follow the Data and Save the Patient!

The Data Strongly Support Bivalirudin!

Pharmacotherapy for Primary PCI - Late Breaking Trials: EUROMAX, HEAT-PPCI, BRIGHT, and BRAVE 4

EUROMAX: Critical Appraisal and Clinical Implications

Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of DES

Post ACC Wrap-up CHAMPION PHOENIX and STREAM

ADAPT-DES One-Year Results: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel and Aspirin Hyporesponsiveness on Patient Outcomes

Discontinuation of Long-Term Clopidogrel Therapy is Associated with Death and Myocardial Infarction after Saphenous Vein Graft Percutaneous Coronary Intervention

Can the Rate of Acute Stent Thrombosis with Bivalirudin Anticoagulation During Primary PCI in STEMI be Reduced with Modified Pharmacologic Regimens?

ADAPT-DES One Year: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel and Aspirin Hyporesponsiveness on Patient Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content